Graft Versus Host Disease Treatment Market

Graft versus Host disease occurs after a stem cell or bone marrow transplant. High dose treatment destroy cancer cells along with that it simultaneously destroys healthy cells. Stem cell and bone marrow transplant treatments are used in reconstructing damaged cells, surrounding cancer tumors. Normally after high dose treatment, patient receives bone marrow from a donor through drip which resumes production of blood cells. Graft versus Host Disease occurs when certain types of white blood cells. This is caused due to the transplanted cells (graft) see recipient?s body (host) as exotic, thus transplanted cells attack the host body.

Graft Versus Host Disease Treatment Market aims to provide a comprehensive presentation of the global market for Graft Versus Host Disease (GVHD) Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Graft Versus Host Disease (GVHD) Treatment. Graft Versus Host Disease Treatment Market contains market size and forecasts of Graft Versus Host Disease (GVHD) Treatment in global, including the following market information:

Global Graft Versus Host Disease (GVHD) Treatment Market Revenue, 2018-2023, 2024-2029, ($ millions)

Global top five companies in 2022 (%)

The global Graft Versus Host Disease (GVHD) Treatment market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

The growing number of organ transplantation cases as one of the major factors that will have a positive impact on the growth of the market. The rise in chronic diseases across the globe has led to the growth in the need for organ transplantation. It has been observed that in 2015, the US witnessed more than 30,000 organ transplants cases, which has increased about 5% when compared to the previous year. Similarly, countries such as Australia also witnesses increasing cases of organ transplantation. This rising number of organ transplants will subsequently augment the growth prospects of the GVHD treatment market.

We surveyed the Graft Versus Host Disease (GVHD) Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Graft Versus Host Disease (GVHD) Treatment Market, by Type, 2018-2023, 2024-2029 ($ millions)

Global Graft Versus Host Disease (GVHD) Treatment Market Segment Percentages, by Type, 2022 (%)

Monoclonal Antibodies

MTOR Inhibitors

Tyrosine Kinase Inhibitors

Thalidomide

Etanercept

Global Graft Versus Host Disease (GVHD) Treatment Market, by Application, 2018-2023, 2024-2029 ($ millions)

Global Graft Versus Host Disease (GVHD) Treatment Market Segment Percentages, by Application, 2022 (%)

Acute Graft Versus Host Disease (aGvHD)

Chronic Graft Versus Host Disease (cGvHD)

Global Graft Versus Host Disease (GVHD) Treatment Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)

Global Graft Versus Host Disease (GVHD) Treatment Market Segment Percentages, By Region and Country, 2022 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Graft Versus Host Disease (GVHD) Treatment revenues in global market, 2018-2023 (estimated), ($ millions)

Key companies Graft Versus Host Disease (GVHD) Treatment revenues share in global market, 2022 (%)

Further, the report presents profiles of competitors in the market, key players include:

Bristol-Myers Squibb

Abbott

AbbVie

Allergan

Anterogen

Astellas Pharma

Athersys

Caladrius

Eli Lilly

GlaxoSmithKline

Glenmark

Kadmon Holdings

Osiris Therapeutics

Sanofi

Takeda

Outline of Major Chapters:

Chapter 1: Introduces the definition of Graft Versus Host Disease (GVHD) Treatment, market overview.

Chapter 2: Global Graft Versus Host Disease (GVHD) Treatment market size in revenue.

Chapter 3: Detailed analysis of Graft Versus Host Disease (GVHD) Treatment company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Graft Versus Host Disease (GVHD) Treatment in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 8: The main points and conclusions of the report.